December 18, 2025

Lilly seeks rapid FDA approval for oral GLP-1 orforglipron after positive obesity “switching” study

2 days ago talkbio0Tagged Approved, Clinical Trials, Eli, Glucagon-Like Peptide 1, injectable incretins, national priority review voucher, Obesity, Oral cavity, orforglipron, Phase 3 trial, United States Food and Drug Administration, Wegovy, weight maintenance, Zepbound

Eli Lilly; orforglipron; oral GLP-1; FDA approval; national priority review voucher; ATTAIN-MAINTAIN trial; obesity treatment; weight maintenance; Zepbound; Wegovy; injectable incretins; Phase 3 trial

GSK strikes RNA-based neuro and kidney disease collaboration with CAMP4 Therapeutics

2 days ago talkbio0Tagged Antisense Oligonucleotides, Antistreptolysin O, CAMP4, Collaboration, gene upregulation, Kidney Diseases, LRPAP1 gene, milestone payments, Neurodegenerative Disorders, Platform, regulatory RNA, RNA therapeutics, royalties, SmithKline Beecham

GSK; CAMP4 Therapeutics; RNA therapeutics; regulatory RNA; antisense oligonucleotides; ASO; RAP Platform; neurodegenerative diseases; kidney disease; renal disease; gene upregulation; biotech collaboration; licensing deal; milestone payments; tiered royalties

Exclusive: Compounding giant Empower Pharmacy cuts hundreds of staff, stops New Jersey operations

2 days ago talkbio0Tagged compounding pharmacy, East Windsor facility, Empower Pharmacy, Facility (object), Glucagon-Like Peptide 1, Inspection (procedure), layoffs, manufacturing shutdown, New Jersey operations, Outsourcing, Qualitative form, United States Food and Drug Administration, Workforce reduction

Empower Pharmacy; compounding pharmacy; layoffs; job cuts; New Jersey operations; East Windsor facility; manufacturing shutdown; outsourcing facility; FDA inspection; Form 483; compounded GLP-1 drugs; workforce reduction

No public results for “Take the Biopharma Sentiment Index” Q1 2026 yet

2 days ago talkbio0Tagged Attitude, Biological Science Disciplines, Biopharma, biopharma executives, Biopharma Sentiment Index, geopolitical risk, M&A activity, Q1 2026, Sentiment, Surveys

Biopharma Sentiment Index; Q1 2026; biopharma executives; life sciences sentiment; 2026 outlook; M&A activity; AI in biopharma; geopolitical risk; survey data

Biopharma’s Winners and Losers of 2025 – Endpoints News recap

2 days ago talkbio0Tagged 2025, Biopharma, Endpoints, Kyle LaHucik, Losers, movers, News [Publication Type], Pharma, Post-Hoc Live, Review [Publication Type], winners

Endpoints News; winners and losers; 2025; biopharma; Post-Hoc Live; Kyle LaHucik; year in review; biotech; pharma; stock movers

Padcev-Keytruda Combination Succeeds Again in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

2 days ago talkbio0Tagged EV-304, Event-Free Survival, KEYNOTE-B15, Keytruda, Malignant neoplasm of urinary bladder, Padcev

Padcev; Keytruda; bladder cancer; KEYNOTE-B15; EV-304; event-free survival

Jim Lang Appointed to the Board of Directors of Halozyme Therapeutics

3 days ago talkbio0Tagged Appointments, Bench International, Biological Factors, BioVie, board of directors, Corporate governance, drug delivery platform, election, Halozyme Therapeutics, Jim Lang

Jim Lang; Halozyme Therapeutics; Board of Directors; appointment; election; Bench International; biopharmaceutical; drug delivery platform; corporate governance; OptimizeRx; BioVie